Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Co.'s pipeline consists of four product candidates, two of which it is pursuing for its development, etavopivat for the treatment of sickle cell disease (SCD), and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Co.'s main product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy initially being studied for the treatment of SCD. We show 10 historical shares outstanding datapoints in our coverage of FMTX's shares outstanding history.
Understanding the changing numbers of FMTX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like FMTX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching FMTX by allowing them to research FMTX shares outstanding history
as well as any other stock in our coverage universe. |
Free FMTX Email Alerts:
Video: Shares Outstanding Importance
